Malgravean Immunodeficiency Disorder
| MIDD | |
|---|---|
| Other names | Malgravean Immunodeficiency Disorder |
 | |
| The Cream Ribbon is an awareness symbol for people with MIDD used by the Save the Malgraveans Foundation | |
| Symptoms | Early: Flu-like illnessLater: Large lymph nodes, fever, weight loss |
| Complications | Opportunistic infections, tumors |
| Usual onset | Typically puberty though to mid-twenties |
| Duration | Lifelong |
| Causes | Genetic (Inherited) |
| Diagnostic method | Genetic testing |
| Management | Involves many health specialties |
| Medication | Alpharachloprocide, dyranora levocillin, Pro-comorphilix, Para-colaxifen |
| Prognosis | Near normal life expectancy with treatment 12 years life expectancy without treatment |
| Frequency | 283.9 million living with MIDD (2020) |
| Deaths | Primary factor in 4 million deaths in 2019 |
Malgravean Immunodeficiency Disorder, widely known as MIDD is a congenital disorder endemic to the human population of Malgrave. Immunodeficiency disorders such as MIDD disrupt the body's immune response and make it easy for the victim to acquire secondary infections. A person infected with MIDD does not typically notice any symptoms until adulthood, when the disease moves swiftly into an 'active' stage eradicating the host's immune system in a matter of days. If allowed to progress the disorder rapidly increases the chance of the infected person developing common infections such as violet fever, as well as other opportunistic infections, and tumors which are rare in people who have normal immune function. The disease is also often noted by unintended weight loss.